Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$ONTY recent news/filings
bullish
## source: finance.yahoo.com
Sun, 07 Jun 2015 13:10:09 GMT ~ How 6 ASCO Biotech Winners Are Focusing on the Future of Cancer
read full: http://247wallst.com/healthcare-business/2015/06/07/how-6-asco-biotech-winners-are-focusing-on-the-future-of-cancer/
*********************************************************
Thu, 04 Jun 2015 11:49:00 GMT ~ Top-Performing Biotech and Drug Stocks During ASCO '15
read full: http://www.thestreet.com/story/13174675/1/top-performing-biotech-and-drug-stocks-during-asco-15.html?puc=yahoo&cm_ven=YAHOO
*********************************************************
Mon, 01 Jun 2015 15:15:00 GMT ~ Are Any Of These On Your 'Penny Stocks To Watch' List
[Accesswire] - CORAL GABLES, FL / ACCESSWIRE / June 1, 2015 / Monday morning saw US stock futures climb suggesting a positive open for Wall Street on the first day of the month. Healthcare and biotechnology stocks have ...
read full: http://finance.yahoo.com/news/penny-stocks-watch-list-151500115.html
*********************************************************
Mon, 01 Jun 2015 14:42:00 GMT ~ Oncothyreon (ONTY) Stock Spikes Following Presentation on Breast Cancer Treatment Candidate
read full: http://www.thestreet.com/story/13170019/1/oncothyreon-onty-stock-spikes-following-presentation-on-breast-cancer-treatment-candidate.html?puc=yahoo&cm_ven=YAHOO
*********************************************************
Mon, 01 Jun 2015 13:40:14 GMT ~ 6 Key Cancer Winners From ASCO Presentations
read full: http://247wallst.com/healthcare-business/2015/06/01/6-key-cancer-winners-from-asco-presentations/
*********************************************************
$ONTY charts
basic chart ## source: stockcharts.com
basic chart ## source: stockscores.com
big daily chart ## source: stockcharts.com
big weekly chart ## source: stockcharts.com
$ONTY company information
## source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/ONTY/company-info
Ticker: $ONTY
OTC Market Place: Not Available
CIK code: 0001412067
Company name: Oncothyreon, Inc.
Company website: http://www.biomira.com
Incorporated In: DE, USA
$ONTY share structure
## source: otcmarkets.com
Market Value: $404,088,997 a/o Jun 09, 2015
Shares Outstanding: 102,301,012 a/o Mar 10, 2015
Float: Not Available
Authorized Shares: Not Available
Par Value: No Par Value
$ONTY extra dd links
Company name: Oncothyreon, Inc.
Company website: http://www.biomira.com
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/ONTY/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/ONTY/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=ONTY+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=ONTY+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=ONTY+Industry
## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/ONTY/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/ONTY/news - http://finance.yahoo.com/q/h?s=ONTY+Headlines
## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/ONTY/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/ONTY/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/ONTY/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/ONTY/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/ONTY/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/ONTY/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/ONTY/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/ONTY/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=ONTY+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/ONTY
DTCC (dtcc.com): http://search2.dtcc.com/?q=Oncothyreon%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Oncothyreon%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Oncothyreon%2C+Inc.&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.biomira.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.biomira.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.biomira.com
## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/ONTY/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/ONTY
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/ONTY/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/ONTY/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/ONTY/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001412067&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/ONTY/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/ONTY/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/ONTY/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/ONTY/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=ONTY&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=ONTY
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/ONTY/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=ONTY+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=ONTY+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=ONTY
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=ONTY
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=ONTY+Cash+Flow&annual
## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/ONTY/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=ONTY+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/ONTY.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=ONTY
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/ONTY/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/ONTY/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/ONTY/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/ONTY/insider-transactions
## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/ONTY
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/ONTY
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/ONTY:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=ONTY
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=ONTY
$ONTY DD Notes ~ http://www.ddnotesmaker.com/ONTY
(ORIG) Prices 28.6M Common Offering at $7/Sharel CEO Economou to Make $10M Purchase(SHORT SELL TO KILL, NOW)$7.14
June 3, 2015 10:34 AM EDT
Ocean Rig UDW (NASDAQ: ORIG) announced that it priced the offering of 28,571,428 shares of its common stock, par value $0.01 per share, at a price of $7.00 per share. The offering is expected to close on June 8, 2015. As part of the offering, George Economou, our Chairman, President and Chief Executive Officer, is purchasing $10 million, or 1,428,571 shares, of common stock in the offering at the public offering price, a number of common shares that maintains his direct ownership in Ocean Rig, representing approximately five percent of its common stock.
Clarksons Platou Securities, Inc., Pareto Securities Inc. and Seaport Global Securities LLC are acting as joint lead managers, joint bookrunners and placement agents in the offering. Clarksons Platou Securities AS and Pareto Securities AS are acting as placement agents. Clarksons Platou Securities AS and Pareto Securities AS are not U.S. registered broker-dealers and to the extent that this offering is made within the United States, their activities will be affected only to the extent permitted by Rule 15a-6 of the Securities Exchange Act of 1934, as amended. The Company intends to use the net proceeds from the offering for working capital and general corporate purposes, including the acquisition of drilling rigs.
The Company's common shares trade on the Nasdaq Global Select Market under the symbol "ORIG."
http://www.streetinsider.com/Corporate+News/Ocean+Rig+UDW+%28ORIG%29+Prices+28.6M+Common+Offering+at+%247Sharel+CEO+Economou+to+Make+%2410M+Purchase/10621535.html?si_email_click=2015060310
What was the all time high on onty.
New to this board, but I've been hearing a lot about ONTY. Seems like a nice setup for a bounce here. What entry levels should I be looking for IYO?
ESI is looking great but iam out, just a liltte. Scare. Thx
ONTY:First short sell,25,639 Shares $4.08 red in bid 8:00 HS
ESI, IS COOL!!
* * $ONTY Video Chart 06-01-15 * *
Link to Video - click here to watch the technical chart video
My fear appears to have come true, with asco finished, there is down pressure. The gap up today needs to fill back down then we can reevaluate
very sweet move today - hope you had a great weekend bud -
Looking very good $EYE$
Go $ONTY
$ONTY 15 min. chart - after the monster Gap Up open above the upper Bollinger Band @ 4.45 the candles worked their way back into the Bands where they found EMA's 4 & 8 support - the candles have been riding EMA's 4 & 8 support ever since - they are the Key support levels to hold - if they break the middle BB @ 4.06 will be on deck - as long as middle BB support holds the up trend should continue -
Fast Sto & RSI are in the overbought/power zone - the MACD Line is still above the Signal Line - very nice volume today - the Key for $ONTY bulls is to bust through the upper BB & test HoD 4.69 resistance -
Huge potential here after asco events. Af even put them on top of the list!
$ONTY Oncothyreon to Present at Jefferies 2015 Healthcare Conference
Source: GlobeNewswire Inc.
Oncothyreon Inc. (Nasdaq:ONTY) announced today that Robert Kirkman, M.D., President and Chief Executive Officer, is scheduled to present at the Jefferies 2015 Healthcare Conference on Wednesday, June 3, 2015 at 11:30 a.m. Eastern Time in New York.
A live and archived webcast of the presentation will be accessible by visiting the Oncothyreon website www.oncothyreon.com under the "News & Events" section.
About Oncothyreon
Oncothyreon is a clinical-stage biopharmaceutical company specializing in the development of innovative therapeutic products for the treatment of cancer. Our goal is to discover, develop and commercialize novel compounds that have the potential to improve the lives and outcomes of cancer patients. Our current clinical-stage product candidates include ONT-380, an orally active and selective small molecule HER2 inhibitor, and ONT-10, a therapeutic vaccine targeting MUC1. We are developing preclinical product candidates in oncology, and potentially certain rare diseases, using our protocell technology. For more information, visit www.oncothyreon.com.
CONTACT: Investor and Media Relations Contact:
Julie Rathbun
Rathbun Communications
206-769-9219
ir@oncothyreon.com
Oncothyreon Inc. logo
How do think ESI now ? I try in. Itz ok? Thanks for hint.
Alert, RST, at any time, purchase , sale price $ 9/10. They want to study the offer for a better price for shareholders
Yeah, iam greedy. I try get more today. Well, so i have hold on and see today. Thanks
Never short sell, from Friday to Monday.Never short sell, from Friday to Monday. Today, if you is in short sell, why not sold more short pre market?
Thanks for hint, also keeping ESI too.
Anything can happen. It is completely shorted
Look for the trend and watch out for sudden changes
Look ESI, IS GOOD!
Lecord, how do think today? Itz going nuts!!!
I am thinking this should treble at least and then pull-back JMHO
ONTY - Sure holds some promise. Tuseday (ASCO) and Wed (jefferies)
Looks like a big day Monday! We're riding a winner here.
ONT-380 has stage IV HER2+ breast cancer patient 'worrying about normal stuff again'
UNIVERSITY OF COLORADO DENVER
SHARE PRINT E-MAIL
IMAGE
IMAGE: AT ASCO 2015, VIRGINIA BORGES, M.D., M.M.SC., AND COLLEAGUES REPORT PROMISING CLINICAL TRIAL RESULTS OF ONT-380 AGAINST HER2+ BREAST CANCER. view more
CREDIT: UNIVERSITY OF COLORADO CANCER CENTER
Promising clinical trial results presented at the American Society for Clinical Oncology (ASCO) Annual Meeting 2015 show activity of the investigational anti-cancer agent ONT-380 against HER2+ breast cancer, in one case specifically against brain metastases and in another case in overall survival of heavily pretreated HER2+ breast cancer patients.
"I am thrilled to have been able to offer this therapy to a patient in her early 40s. She didn't have any other great treatment options that we would have expected to have any meaningful impact, especially on her brain. Now she's been on the study over a year. The mets in her body are gone and the brain lesion has shrunk down to a little nubbin. She's living a normal life, fretting about the family business and how the kids are doing - normal stuff," says Virginia Borges, MD, MMSc, director of the Breast Cancer Research Program and Young Women's Breast Cancer Translational Program at the University of Colorado Cancer Center and one of the study's authors.
Both sets of results being presented are from ongoing phase 1b clinical trials of ONT-380, one in combination with the drug TDM-1, and the other in combination with capecitabine and/or trastuzumab. Women on these studies include those whose disease had progressed after at least two previous rounds of therapy (sometimes including previous drugs used to target HER2).
In the first study of ONT-380 with TDM-1, all 8 evaluable patients experienced more than 50 percent reduction in primary brain tumor size.
"This drug has the potential to be the long-awaited, needed therapy that targets brain metastases in HER2+ brain cancer, and could even someday be used to prevent brain metastases in the first place," says Borges.
The second study presents overall response rates from a similar, ongoing phase 1b clinical trial of ONT-380 with capecitabine and/or trastuzumab. Of 8 heavily pretreated patients enrolled on the study, 4 showed partial response (reduction in tumor size of more than 30 percent), 2 achieved stable disease, and 2 progressed.
In about 25 percent of the 1-in-8 women who will develop breast cancer during their lifetimes, the HER2 gene creates an abnormal amount of HER2 protein, which acts as a "receptor" for human epidermal growth factor. The presence of more HER2 receptors allows a cell to trap more growth-promoting hormones, which tells the cell to grow in an out-of-control, cancerous way.
ONT-380, invented by Array Biopharma in Boulder, CO and now being developed by Oncothyreon in Seattle, WA, is a small molecule inhibitor of the HER2 growth factor receptor. The drug works by targeting the HER2 "tyrosine kinase" - a link in the chain of communication that allows HER2 receptors to signal the growth of the cell. The fact that it is a small molecule means the drug is able to pass through the blood-brain barrier to act against brain metastases of the disease. HER2+ breast cancer is more likely to affect younger women and also more likely than other breast cancers to metastasize specifically to the brain.
"Usually we expect the results of a phase 1 clinical trial to give us data that we can use to guide the results of future treatments. This is a great case in which, for many of these patients, the results were immediate. There are women who are alive today because of this drug," Borges says.
###
Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.
SHARE PRINT E-MAIL
Media Contact
Erika Matich
erika.matich@ucdenver.edu
@CUDenver
http://www.ucdenver.edu
More on this News Release
ONT-380 has stage IV HER2+ breast cancer patient 'worrying about normal stuff again'
UNIVERSITY OF COLORADO DENVER
MEETING
2015 ASCO Annual Conference
KEYWORDS
******TThanks to a posting on InvestorVillage today
Wow, iam out money just wait.
(RST) Announces Receipt of Interest from RDG Capital Fund Management; Will Evaluate(OPPORTUNITY)
May 29, 2015 9:29 AM EDT
Rosetta Stone (NYSE: RST) announced that its Board of Directors has received an expression of interest from RDG Capital Fund Management. The Board stated that it will carefully evaluate the expression of interest. The Board also said that the Company is actively implementing its strategic plan, which it believes will deliver attractive value for shareholders.
http://www.streetinsider.com/Corporate+News/Rosetta+Stone+%28RST%29+Announces+Receipt+of+Interest+from+RDG+Capital+Fund+Management%3B+Will+Evaluate/10607138.html?si_email_click=2015052909
Look, TBIO, Pre market $2.72+ 44% PBMD $2.81+14%
Good news
Chart looking solid golden cross coming-reconranger
A sell signal for these stocks: Oncothyreon Inc (USA) (NASDAQ:ONTY), Avago Technologies Ltd (NASDAQ:AVGO), Delcath Systems, Inc. (NASDAQ:DCTH)
Developed J. Welles Wilder, the Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI is an extremely popular momentum indicator that has been featured in a number of articles, interviews and books over the years. In particular, Constance Brown’s book, Technical Analysis for the Trading Professional, features the concept of bull market and bear market ranges for RSI. Andrew Cardwell, Brown’s RSI mentor, introduced positive and negative reversals for RSI. In addition, Cardwell turned the notion of divergence, literally and figuratively, on its head.
RSI oscillates between zero and 100. Traditionally, and according to Wilder, RSI is considered overbought when above 70 and oversold when below 30. Signals can also be generated by looking for divergences, failure swings and centerline crossovers. RSI can also be used to identify the general trend.
Oncothyreon Inc (USA) (NASDAQ:ONTY) is now in overbought territory with an RSI value of 77.56. The stock is up +106.13% in one month through last close, to $3.36, showing a +108.70% return during the past three months. The share price is up from fifty two week low with +138.30% and low from fifty two week high with -6.67%. It stands +86.65% above the average-price of 50 days and +72.22% compared with the SMA 20.
Avago Technologies Ltd (NASDAQ:AVGO) has a RSI reading of 74.14, with a 1-year total return of +102.35% and a six-month return of +57.88%. The stock is up +17.76% in one month through last close, to $141.49, showing a +25.94% return during the past three months. The share price is up from fifty two week low with +108.03% and up from fifty two week high with +3.82%. It stands +12.65% above the average-price of 50 days and +14.07% compared with the SMA 20.
Delcath Systems, Inc. (NASDAQ:DCTH) currently has an RSI of 79.90. The stock is up +39.22% in one month through last close, to $1.42, showing a +19.33% return during the past three months. The share price is up from fifty two week low with +77.50% and low from fifty two week high with -52.67%. It stands +48.26% above the average-price of 50 days and +62.94% compared with the SMA 20.
http://www.wsobserver.com/a-sell-signal-for-these-stocks-oncothyreon-inc-usa-nasdaqonty-avago-technologies-ltd-nasdaqavgo-delcath-systems-inc-nasdaqdcth/7216402/
The main Chart in shorted.This chart is very important for an investor.
http://stockcharts.com/freecharts/gallery.html?s=ONTY
Thank you Lecorb. Today is low
Comparative analysis: SHORTED TOTAL.
ONTY VS S&P 500 INDEX + 125%
ONTY VS USA/HEALTH CARE +125%
ONTY VS USA/BIOTECHNOLOGY +125%
-------------------------
SLTD:Markit short selling activity:Low, Be careful
ONTY: Big short sell,101,875 $3.44 11:14 hs +98,773 shares in short $3.42 11:15
Any time, again in fallen!
OHGI is cool
Thanks lecorb, great site stock ref. I keep in eye am market may jump in back.
AMERICAN BULLS:STAY LONG,LAST PATTERN:BEARISH HARAMI
Signal Update
Our system’s recommendation today is to STAY LONG. The previous BUY signal was issued on 05/14/2015, 13 days ago, when the stock price was 1,7530. Since then ONTY has risen by +91,67%.
Market Outlook
Candlesticks warned us today to be on alert with a new bearish pattern. Market attention is now on the downside.more...
https://www.americanbulls.com/SignalPage.aspx?lang=en&Ticker=ONTY
Glad to see you got out. Way too much downside coming imo
Thanks for FYI...,
Cool!!!
Pay close attention to CERE
Ceres Sprouts Off Patent Awarded For Soybean Seed Enhancement
2:53 pm ET May 27, 2015 (Benzinga)
Joel Elconin is the co-host of Benzinga's #PreMarket Prep, a daily trading idea radio show.
Ceres Inc (NASDAQ: CERE) shares are trading higher by $1.46 at $3.14 in Wednesday's session. The catalyst for the doubling of the agricultural biotechnology company is U.S. patent awarded for a genetic sequence derived from soybean, covering uses of the gene in areas such as research, product development and plant transformation.
The low-priced volatile issue spiked to the $4 level for the fifth time since March 4, but has not been able to sustain that level for more than one session. That is the case in Wednesday's session as Ceres spike from its low for the day ($1.77) to $4 on the heels of the announcement before retreating to its current level.
It should be noted that other spikes in the issue took place on average volume.
However, the current rally is taking place on much higher than average volume, as 12.3M shares have changed hands compared with its 20-day average of 1M shares with two hours remaining in the session.
Again, thanks iam out@3.60 and save. couple k. So now iam waiting and see whatever.
Oh, thanks... I need to do some chart studying...
ONTY:Markit short selling activity, It is increasing from low to médium.
ONTY must come down to find your balance in the chart. RSI(14)82.28
I'm pretty new to this what does all that mean?...
Followers
|
61
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
792
|
Created
|
05/16/06
|
Type
|
Free
|
Moderators |
company web-site - http://www.oncothyreon.com
recent event / CC - http://ir.oncothyreon.com/events.cfm -
Oncothyreon is a biotechnology company dedicated to the development of oncology products that can improve the lives and outcomes of cancer patients. We are currently developing multiple therapeutic candidates designed to target cancer in specific and effective ways. Our pipeline includes both synthetic vaccines and small molecules for a variety of cancer indications. Oncothyreon is headquartered in Bellevue, Washington. The Company is traded on the NASDAQ National Market under the symbol ONTY and on the Toronto Stock Exchange under the symbol ONY. We are The Cancer Vaccine People(TM).
Stimuvax
ONTY's drug Stimuvax, in partnership with Merck KGaa, is now in large Phase 3 Pivotal Trial program for NSCLC:
Phase III NSCLC (Lung) "START" Trial - http://www.clinicaltrials.gov/ct2/show/NCT00409188
Phase III NSCLC "INSPIRE" Trial (Asia) - http://www.clinicaltrials.gov/ct2/show/NCT01015443
Phase II NSCLC w/Avastin Trial - http://www.clinicaltrials.gov/ct2/show/NCT00828009
Phase I/II NSCLC Trial in Japan - http://www.clinicaltrials.gov/ct2/show/NCT00960115
Phase IV Long-Term Safety Trial - http://www.clinicaltrials.gov/ct2/show/NCT01423760
Phase II HDPC Trial - http://bethesdatrials.cancer.gov/clinical-research/search_detail.aspx?ProtocolID=NCI-11-C-0247
Pipe-Line - http://www.oncothyreon.com/pipeline/overview.html
Remaining Pipe-Line -
ONT-10 - http://www.oncothyreon.com/pipeline/vaccines/ONT-10/overview.html
PX-866 - http://www.oncothyreon.com/pipeline/small/PX-866/overview.html
Start of Trial with Taxotere - http://ir.oncothyreon.com/releasedetail.cfm?ReleaseID=526661
Start of Trial with Erbitux - http://ir.oncothyreon.com/releasedetail.cfm?ReleaseID=537953
PRESS RELEASES
Oncothyreon Initiates Phase 2 Trial of its PI-3 Kinase Inhibitor PX-866 in Patients with Glioblastoma - http://ir.oncothyreon.com/releasedetail.cfm?ReleaseID=561867
Oncothyreon Presents Preclinical Data for ONT-10 and PX-866 at American Association for Cancer Research - http://ir.oncothyreon.com/releasedetail.cfm?ReleaseID=561521
Oncothyreon Announces Publication of Safety & Survival Data From Stimuvax Phase 1/2 NSCLC Trial - http://ir.oncothyreon.com/releasedetail.cfm?ReleaseID=515788
Oncothyreon Initiates Phase 1/2 Trial of its PI-3 Kinase Inhibitor PX-866 in Combination with Cetuximab - http://ir.oncothyreon.com/releasedetail.cfm?ReleaseID=537953
Oncothyreon announces that Merck Serono is resuming the Stimuvax clinical program in lung cancer - http://ir.oncothyreon.com/releasedetail.cfm?ReleaseID=480296
Oncothyreon announces temporary suspension of Stimuvax clinical trials - http://ir.oncothyreon.com/releasedetail.cfm?ReleaseID=453976
Oncothyreon announces STRIDE Phase 3 BC trial - June 22, 2009 http://investorshub.advfn.com/boards/read_msg.aspx?message_id=38926533
Oncothyreon announces clinical data at ASCO - May 30, 2009 - http://investorshub.advfn.com/boards/read_msg.aspx?message_id=38259984
Oncothyreon announces development plans - Dec. 18, 2008 - http://biom.client.shareholder.com/releasedetail.cfm?ReleaseID=355043
Merck KGaA buys manufacturing rights for Stimuvax - Dec. 18, 2008 - http://biom.client.shareholder.com/releasedetail.cfm?ReleaseID=355037
ONTY/Merck KGaA amend agreements - Aug 8, 2007http://www.marketwatch.com/news/story/biomira-merck-kgaa-sign-amended/story.aspx?guid=%7B43FD62A1%2D....
MEDICAL PRESENTATIONS
ASCO 2007 Stimuvax Abstract - http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=47&abstractID=32165
"16 pts were evaluated for this interim safety analysis ..........As of September 2006, 10 pts were still on study treatment."
ASCO 2008 Stimuvax Abstract - http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=34755
"The 2-year survival rate of 64% ....compares favorably with previously reported survival for chemoradiation in stage III NSCLC."
ASCO 2009 Stimuvax Abstract - http://www.abstract.asco.org/AbstView_65_31704.html
"a remarkable # of pts received prolonged treatment...16 pts received L-BLP25 for 2.0-7.7 years, 10 pts were treated for >5 years."
COMPLETE MEDICAL PAPERS
Paper summarizing all Stimuvax trials to date - http://investorshub.advfn.com/boards/read_msg.aspx?message_id=39761211
Publication of Data From Phase 1/2 NSCLC Trial - http://ir.oncothyreon.com/releasedetail.cfm?ReleaseID=515788
A Peptide Vaccine Strategy in NSCLC - http://investorshub.advfn.com/boards/read_msg.aspx?message_id=39627241
Phase IIb Trial in NSCLC Stage IIIB and IV - http://investorshub.advfn.com/boards/read_msg.aspx?message_id=39099793
"The greatest difference in survival was observed in stage IIIB LR patients (adjusted HR = 0.524; 95% CI, 0.261 to 1.052; P = .069)"
- Fig 3. Overall survival by study arm - http://jco.ascopubs.org/cgi/content-nw/full/23/27/6674/F3
- Fig 4. Survival analysis for stage IIIB with MFE or stage IV patients - http://jco.ascopubs.org/cgi/content-nw/full/23/27/6674/F4
- Fig 5. Survival analysis for stage IIIB locoregional patients - http://jco.ascopubs.org/cgi/content-nw/full/23/27/6674/F5
Detailed Description of START Trial - http://investorshub.advfn.com/boards/read_msg.aspx?message_id=39062424
First Interim Look - http://investorshub.advfn.com/boards/read_msg.aspx?message_id=58060227
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |